Ultrafast MRI Imaging to Exclude Constipation
FIESTA
Use Of Ultrafast MRI Imaging (FIESTA) In Diagnosis Of Suspected Constipation In Haematological Malignancy and Immunocompromised Patients
1 other identifier
interventional
11
1 country
1
Brief Summary
In haematological malignancy and in immunocompromised patients, constipation is a common symptom caused by a number of factors during treatment. In current clinical practice, an abdominal radiograph is the first imaging investigation for constipation and non specific abdominal pain to support or exclude the clinical suspicion. Children are more sensitive to radiation induced adverse effects especially in the thyroid gland and bone marrow. Immunocompromised patients are at risk of developing a second malignant neoplasm. MRI is an alternative imaging modality without ionizing radiation. Imaging the peritoneal cavity on abdominal MRI has always been challenging primarily because of bowel motion and a long acquisition time for standard T1 and T2 weighted sequences. Recent development of an ultrafast 2 dimensional FIESTA sequence developed by GE (General Electric) Healthcare based on the balanced steady state free precession (b-SSFP) pulse sequence has several advantages: motion insensitivity ( does not interfere with peristalsis), sharp edge definition and higher contrast when compared with the standard SSFSE pulse sequence. FIESTA is well suited for abdominal imaging as it produces motion- free images, allowing clear delineation of intra-peritoneal and retroperitoneal anatomy and is capable of depicting the vascular anatomy and lymph-adenopathy.There is a wide spectrum of diseases which could cause abdominal pain in our study group with constipation being the most common cause but MRI could potentially detect more serious bowel-related chemotherapy induced complications such as typhlitis, pneumatosis coli, veno-occlusive disease, pancreatitis and intra abdominal abscess, which would not be apparent on abdominal radiograph.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2012
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 23, 2015
CompletedFirst Posted
Study publicly available on registry
January 18, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedOctober 13, 2017
July 1, 2017
1.6 years
April 23, 2015
October 12, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Correlation between constipation scores for abdominal radiographs and FIESTA MRI
Correlation between constipation scores for abdominal radiographs and FIESTA MRI
Day 1
Secondary Outcomes (2)
Inter-rater correlation of constipation scores
Day 1
Observed, clinically relevant, additional findings on MRI compared to abdominal radiographs as assessed by the scoring radiologist at the time of review
Day 1
Study Arms (1)
MRI group
OTHERUltrafast MRI
Interventions
Eligibility Criteria
You may qualify if:
- Patients with haematological malignancy or immunocompromise under the care of the haematology team and undergoing plain abdominal radiograph for abdominal pain as part of routine clinical care.
- Patients who can stay still in MRI
- Patient age between 6 and 18 years.
You may not qualify if:
- Patients who require sedation or general anesthesia.
- Those with signs of acute abdomen.
- Claustrophobic patient.
- Patient/parents who are unable to wait for MRI.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sheffield Children's NHS Foundation Trust
Sheffield, Sheffield (South Yorkshire District), S10 2TH, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Hughes
Investigator
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2015
First Posted
January 18, 2016
Study Start
September 1, 2012
Primary Completion
April 1, 2014
Study Completion
July 1, 2017
Last Updated
October 13, 2017
Record last verified: 2017-07